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Abstract
Background: Toll-like receptors (TLRs) play a crucial role in the activation of innate immunity in response to many viruses.
We previously reported the implication of TLR2 in the recognition of Epstein-Barr virus (EBV) by human monocytes. Because
murine gammaherpesvirus-68 (MHV-68) is a useful model to study human gammaherpesvirus pathogenesis in vivo,w e
evaluated the importance of mouse TLR2 in the recognition of MHV-68.
Methodology/Principal Findings: In studies using transfected HEK293 cells, MHV-68 lead to the activation of NF-kB reporter
through TLR2. In addition, production of interleukin-6 (IL-6) and interferon-a (IFN-a) upon MHV-68 stimulation was reduced
in murine embryonic fibroblasts (MEFs) derived from TLR22/2 and MyD882/2 mice as compared to their wild type (WT)
counterpart. In transgenic mice expressing a luciferase reporter gene under the control of the mTLR2 promoter, MHV-68
challenge activated TLR2 transcription. Increased expression levels of TLR2 on blood granulocytes (CD115
2Gr1
+) and
inflammatory monocytes (CD115
+Gr1
+), which mobilized to the lungs upon infection with MHV-68, was also confirmed by
flow cytometry. Finally, TLR2 or MyD88 deficiency was associated with decreased IL-6 and type 1 IFN production as well as
increased viral burden during short-term challenges with MHV-68.
Conclusions/Significance: TLR2 contributes to the production of inflammatory cytokines and type 1 IFN as well as to the
control of viral burden during infection with MHV-68. Taken together, our results suggest that the TLR2 pathway has a
relevant role in the recognition of this virus and in the subsequent activation of the innate immune response.
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Introduction
MHV-68 is a virus naturally present in rodent populations [1].
It is genetically and biologically related to the two major human
gammaherpesviruses, Epstein-Barr virus (EBV) and Kaposi’s
sarcoma-associated herpesvirus (KSHV) [2]. MHV-68 is known
to infect its host through nasopharyngeal tissues where a primary
lytic replication occurs in lung epithelial cells. Replication in the
lungs subsequently leads to infected cell migration to the lymphoid
tissues and establishment of a latent state mainly in B lymphocytes
[3,4,5,6] and macrophages [7].
During the last decade, several reports have highlighted the
crucial role of the TLR system in host defense against microbial
agents. In this regard, many members of the herpesvirus family
have already been shown to activate TLRs. For example, different
cell populations infected by herpes simplex virus 1 or 2 (HSV-1
and HSV-2) were found to secrete robust levels of type 1 IFN, IL-6
and tumor necrosis factor-a (TNF-a) through the activation of
TLR2 and TLR9 [8,9,10]. Human cytomegalovirus (CMV) and
varicella-zoster virus (VZV) are other members of the herpesvirus
family known to activate an inflammatory response through TLR2
[11,12]. In addition, we previously showed that EBV is recognized
by TLR2 and that this recognition event leads to monocyte
chemotactic protein-1 (MCP-1) secretion by human monocytes
[13]. Regarding MHV-68, recent studies have shown interactions
between this virus and the TLR system. For example, the increase
of lytic and latent viral loads observed in spleen, but not in lungs of
TLR92/2 mice as compared to control groups suggest that
TLR9 is important in organ-specific immunity against MHV-68
during both lytic and latent infection [14]. The MyD88 adaptor
protein is required for downstream signaling by all TLRs except
TLR3. In its absence, a decrease in the frequency of MHV-68
viral genome-positive B cells was observed in spleens of mice
suggesting that the MyD88 pathway contributes to the control of
MHV-68 latency establishment in B cells [15]. Lastly, the
transcription factor NF-kB, which can be activated through
MyD88, also seems to regulate MHV-68 latency establishment
and its maintenance in B cells [16]. In fact, NF-kB p502/2 mice
showed increase and persistent viral replication in lungs when
compared to WT mice, suggesting that NF-kB p50 is required for
immune control by the host.
While cytokine production during infection of mice with MHV-
68 has been reported [14,17], little is known about the
contribution of the TLR system in such production. In addition,
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13742a recent report identified TLR2 as a mediator of type 1 IFN
secretion in response to viral ligands [18]. Because several
herpesviruses were reported to activate TLR2, we investigated
the implication of this TLR in the early innate response against
MHV-68. Our results indicate that during acute infection with
MHV-68, TLR2 signaling via MyD88 is an important aspect of
the proinflammatory and antiviral responses directed against this
virus.
Results
MHV-68 activates NF-kB through TLR2
We previously demonstrated that EBV induces MCP-1
secretion by human primary monocytes via the TLR2/NF-kB
signaling pathway [13]. In order to investigate whether MHV-68
could be recognized by TLR2, HEK293 cells were transiently co-
transfected with a control vector or with a murine TLR2 (mTLR2)
expression plasmid along with a NF-kB luciferase reporter
plasmid. Transfected cells were then stimulated with increasing
multiplicities of infection (m.o.i.) of MHV-68 or with the synthetic
TLR2 ligand Pam3CSK4. NF-kB activation, as measured by
luciferase activity, was observed in TLR2-expressing cells
stimulated with Pam3CSK4 indicating functional TLR2 expres-
sion (Figure 1). Upon MHV-68 stimulation, dose-dependent NF-
kB activation was a consequence of TLR2 triggering by the virus
since no significant luciferase activity was observed in cells
transfected with the control vector. Thus, this first set of
experiment shows that MHV-68 has the capacity to induce the
activation of NF-kB in transfected cells expressing mTLR2.
TLR2 and MyD88 are involved in MHV-68-induced
production of IL-6 and type 1 IFN
TLR2 activation leads to the production of proinflammatory
cytokines via the MyD88 adaptor molecule. Since MEFs express all
TLRs in a functional state and can secrete a wide range of cytokines
[19], we isolated this cell type from WT and various mutant mice in
order to study TLR2-dependent cytokine secretion in response to
MHV-68. First, WT and TLR22/2 MEFs were stimulated with
lipopolysaccharide (LPS) or were infected with increasing virus
m.o.i. (Figure 2A) and cell culture supernatants were tested for the
production of the proinflammatory cytokine IL-6. Cytokine
production upon treatment with LPS, a TLR4 agonist, was
TLR2-independent. However, at all MHV-68 m.o.i. tested, IL-6
production by TLR2-deficient MEFs was significantly reduced in
comparison to WT cells. TLR2-dependent IL-6 production was
detected as early as 6 hours post-infection and was sustained at 18
and 24 hours (Figure 2B). Ultraviolet (UV) irradiation of MHV-68
inhibitsitspotentialtoreplicatebutdoesnotaffectitsstructurewhile
heat inactivation disrupts viral particle integrity [13]. Although
substantiallyreduced inWTcells treated with UV-irradiated viruses
as compared to infectious viruses, IL-6 levels still depended on
TLR2 indicating that viral replication is dispensable to induce
production of IL-6 upon TLR2 recognition (Figure 2C). Heat-
inactivated viral preparations did not lead to IL-6 release by MEFs
indicating that cytokine secretion required integrity of MHV-68
particles (data not shown). Since MyD88 is required for signaling by
most TLRs, we investigated its role in IL-6 secretion in response to
MHV-68. As shown in Figure 2D, IL-6 secretion induced by LPS
(TLR4 agonist) and Pam3CSK4 (TLR2 agonist) was totally
abolished in the absence of MyD88. The same was observed upon
infection by MHV-68 highlighting the importance of the TLR2-
MyD88 pathway for IL-6 secretion in response to the virus. Finally,
in light of the recent findings that TLR2 activation by viral, but not
bacterial ligands could lead to the production of type 1 IFN, we
investigated whether TLR2-dependent MHV-68 recognition leads
to type 1 IFNsecretion.Lipoteichoic acid (LTA), a bacterial-derived
TLR2 agonist,didnot lead to IFN-a secretion byMEFs(Figure2E).
The viral synthetic agonist poly(I:C) is known to activate TLR3 via
the TRIF adaptor molecule and activate IFN-a secretion. Indeed,
TRIF-dependent IFN-a secretion was observed upon poly(I:C)
treatment. When cells were infected with MHV-68, IFN-a
production was significantly reduced in the absence of TLR2 and
almost completely abolished in the absence of MyD88 while
remaining unaffected in TRIF-deficient cells. MHV-68 did not lead
to significant IFN-b secretionby MEFs (data not shown).Therefore,
these data indicate that proinflammatory cytokine and type 1 IFN
production induced by MHV-68 viral particles can occur via
MyD88-dependent TLR2 signaling.
MHV-68 activates TLR2 transcription in vivo
It has been shown that infection with viruses such as influenza A
virus can induce an upregulation in TLR2 expression by human
neutrophils [20]. This strategy may be beneficial to the virus in
order to induce upregulation of viral entry receptors but may also
serve the host in favoring a rapid respond to viral invaders [21,22].
We therefore investigated whether MHV-68 could induce the
activation of TLR2 transcription during an acute infection in a
living animal model. For that matter, we used transgenic mice
expressing a luciferase reporter gene driven under the transcrip-
tional control of mTLR2 promoter (TLR2-luc). Since TLR2-luc
was only slightly expressed in the lungs upon intranasal (in.)
infection with MHV-68 (data not shown), we performed intraper-
itoneal (ip.) injections of the virus. As shown in Figure 3A, luciferase
activity was detected in the region surrounding inguinal lymph
nodes in the peritoneal cavity of TLR2-luc mice following ip.
injection with MHV-68. The lack of luciferase activity in mice
injected with mock control confirms the MHV-68-specific activa-
tion of TLR2 transcription. To evaluate whether viral replication is
involved in the induction of TLR2 transcription, TLR2-luc mice
were treated with UV-irradiated MHV-68 particles. Levels of
bioluminescence observed were similar when compared to mice
injected with infectious viruses indicating that the direct detection of
MHV-68 particles is sufficient to induce TLR2 transcription in
Figure 1. MHV-68 activates TLR2 in transfected HEK293 cells.
HEK293 cells were transiently transfected with either murine TLR2 or
control plasmid (400 ng) along with NF-kB luciferase reporter plasmid
(100 ng). Forty-eight hours post-transfection, cells were stimulated with
mock, infectious MHV-68 (m.o.i. 0.1, 0.5 and 1) or Pam3CSK4 (Pam, 1 mg/
ml) for 6 hours followed by luciferase assay. Data are representative of
two different experiments. Values that were significantly different
(p,0.05) from mock control are indicated (*).
doi:10.1371/journal.pone.0013742.g001
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observed was a direct consequence of MHV-68 infection, DNA
from major lymph nodes present in the abdominal region (inguinal
and lumbar lymph nodes) of mice was extracted and the presence of
MHV-68 gB gene was tested by qPCR. As shown in Figure 3B,
MHV-68 gB transcript was detected in all three lymph nodes as
soon as 6 hours following infection and decreased after 48 hours of
infection. Taken together, bioluminescence and qPCR data
demonstrate that MHV-68 stimulation can induce transcriptional
activation of TLR2 in vivo.
Expression of TLR2 by cells recruited to the lungs of
MHV-68 infected mice
Monocytes and neutrophils are known to respond to microbial
stimuli by trafficking to infected tissues and secreting inflammatory
cytokines. Having determined that MHV-68 can activate TLR2
transcription in vivo, we next wanted to investigate whether lung
infiltrating cells, specifically granulocytes and monocytes, express
the TLR2 receptor on their surface. Mice were thus infected with
MHV-68 via the in. route and the presence of those cell populations
inisolatedlungswas analyzed byflowcytometry. Cellswere labelled
with anti-CD115, anti-Ly6C (Gr1
+), which allows to discriminate
between granulocytes and monocytes (reviewed in [23]), and with
anti-TLR2 antibodies to measure its expression. As shown in
Figure 4, MHV-68 infection induced significant recruitment of
inflammatory cellsinto the lungsof mice, as compared to uninfected
control. Those cells seem to mainly correspond to granulocytes
(CD115
2Gr1
+) and to two subpopulations of monocytes, one
referred to as patrolling monocytes (CD115
+Gr1
2) and the other as
inflammatory monocytes (CD115
+Gr1
+). This cell recruitment
correlated with an increased percentage of TLR2 positive cells since
granulocytes (CD115
2Gr1
+) and inflammatory monocytes
(CD115
+Gr1
+) expressed higher levels of TLR2 receptor on their
surface as reflected by an increased in mean fluorescence intensity
(MFI). Thus, MHV-68 induces migration of TLR2-expressing
inflammatory cells in the lung of infected mice.
TLR2- and MyD88-dependent type 1 IFN production and
control of viral burden following pulmonary MHV-68
infection
Type 1 IFNs are critical for the control of viral infection and mice
deficient in the IFN-a/b receptor arehighly susceptible to MHV-68
infection ([24] and reviewed in [25]). Since we observed that TLR2
contributes to IFN-a secretion by MEFs infected with MHV-68
(Figure 2E), we wanted to determine if this was also the case in vivo,
following pulmonary infection. WT, TLR22/2 and MyD882/2
mice were thus infected in. with MHV-68 for 24 hours and lungs
were harvested for type 1 IFN determination. IFN-a levels were
significantly reduced in the lungs of infected TLR22/2 and
Myd882/2 mice as compared to WT mice (Figure 5A). A similar
Figure 2. Inflammatory response to MHV-68 in MEFs is dependent on TLR2 expression. (A) WT and TLR22/2 MEFs were stimulated with
mock, infectious MHV-68 at indicated m.o.i. or LPS (1 mg/ml) for 18 hours. Cell-free supernatants were then assessed for IL-6 secretion by ELISA assay.
(B) WT and TLR22/2 MEFs were stimulated with mock or infectious MHV-68 (m.o.i. of 1) for indicated periods of time or with LPS (1 mg/ml, 18 hours).
Cell-free supernatants were then assessed for IL-6 secretion. (C) WT and TLR22/2 MEFs were stimulated with mock, infectious MHV-68, UV-irradiated
MHV-68 (m.o.i. of 1) or LPS (1 mg/ml) for 24 hours and cell-free supernatants were then assessed for IL-6 secretion. (D) WT, TLR22/2 and MyD882/2
MEFs were stimulated with mock or infectious MHV-68 (m.o.i. of 1) for 24 hours and 48 hours or with LPS (1 mg/ml) or Pam3CSK4 (Pam, 1 mg/ml) for
48 hours and cell-free supernatants were then assessed for IL-6 secretion. (E) WT, TLR22/2, MyD882/2 and TRIF2/2 MEFs were stimulated with
mock or with infectious MHV-68 (m.o.i. of 1), LTA (10 mg/ml) or poly(I:C) (5 mg/ml, transfected with Lipofectamine) for 24 hours. Levels of IFN-a were
then determined in cell-free supernatants by ELISA. Data are representative of three different experiments. *p,0.05.
doi:10.1371/journal.pone.0013742.g002
TLR2 Recognizes MHV-68
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13742trend was observed for IFN-b albeit only reaching statistical
significance for infected MyD882/2 mice (Figure 5B). In order to
investigate the contribution of TLR2 in MHV-68 clearance in vivo,
WT, TLR2- and MyD88-deficient mice were infected in. with
MHV-68 and lungs were harvested at day 3 and 5 following
infection for viral load determination. Increased viral load observed
in TLR22/2 mice after 5 days of infection (Fig. 5C) indicates that
TLR2 has a protective role in early defense against MHV-68
infection.However,the absenceofincreaseinviralburdenobserved
at day 3 in mice lacking TLR2 indicates that other mechanisms
dependent on MyD88 signaling may be involved in viral clearance
since an increase in viraltiters wasobserved inMyD882/2 mice at
both 3 and 5 days post-infection. We also assessed the level of IL-6
secretion in lungs of mice treated under the same experimental
conditions. After 3 days of infection with MHV-68, both WT and
TLR22/2 mice secreted similar IL-6levelsinthelung tissue,while
MyD882/2 mice showed reduced IL-6 lung concentrations
(Fig. 5D). At day 5 post-infection, both MyD882/2 and
TLR22/2 mice had reduced lung IL-6 concentrations when
compared to WT mice. Therefore, TLR2 signaling via MyD88 is
important to control viral replication in the early stages of
pulmonary MHV-68 infection.
TLR2 mediates production of inflammatory mediators in
different tissues
To further investigate whether recognition of MHV-68 by TLR2
is restricted or not to the lungs, we compared the production of IL-6
Figure 3. TLR2 transcription is upregulated during MHV-68 infection. (A) Bioluminescence assay of TLR2-LUC-AcGFP transgenic mice
injected ip. with mock control, infectious MHV-68 or UV-irradiated MHV-68 for 6 hours, 24 hours and 48 hours. (B) Quantitative PCR of MHV-68 gB
sequence from DNA extraction of inguinal and lumbar lymph nodes of mice infected with infectious MHV-68. MHV-68 genomic DNA was used as a
positive control. Data are representative of three different experiments. p.i.: post-infection.
doi:10.1371/journal.pone.0013742.g003
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MHV-68. This time, WT, TLR22/2 and MyD882/2 micewere
treated by intravenous (iv.) administration of UV-irradiated MHV-
68 particles to avoid interference with other sensors activated by
viral replication, and secretionlevels of IL-6, IFN-a and IFN-b were
assessed insera, lungsand spleens.Asshown inFigure6,production
of IL-6 was partially reduced in lungs and significantly reduced in
spleens of TLR2-deficient mice. Such reduction was enhanced in
the lungs and similar in the spleen of MyD882/2 mice suggesting
that secretion of IL-6 in response to MHV-68, especially in the
lungs, could be regulated through other mechanisms than TLR2
alone. On the other hand, production of IFN-a and IFN-b was
similarly reduced in all tissues isolated from both strains of deficient
mice as compared to WT animals. Therefore, TLR2-dependent
MHV-68 recognition upon systemic challenge is not restricted to
the lungs and contributes to early IL-6 and type 1 IFN secretion in
multiple tissues.
Discussion
MHV-68 is known to induce the secretion of a wide range of
cytokines including IL-6, IL-10, IL-12, type 1 IFN, and IFN-c
Figure 4. Expression of TLR2 in lungs of MHV-68-infected mice. (A and B) WT mice were left uninfected (A) or were infected in. with MHV-68
for 24 hours (B). Cells were isolated from lungs and stained with anti-CD115, anti-Gr1 and anti-TLR2 antibodies as detailed in the Materials and
methods section. (C) The percentage of different cell subpopulations expressing TLR2 was determined by flow cytometry. Data are representative of
two different experiments. MFI: Mean Fluorescence Intensity. Black lines: not infected. Coloured histograms: MHV-68-infected.
doi:10.1371/journal.pone.0013742.g004
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proinflammatory cytokine IL-6 and of type 1 IFN induced by
MHV-68 significantly relies on TLR2- and MyD88-dependent
signaling. Importantly, TLR22/2 mice were impaired in their
ability to control viral replication in the lungs after five days of
infection, suggesting that an effective response against MHV-68 is
regulated through this cell membrane receptor. TLR2 gene
expression was rapidly induced following MHV-68 challenge, an
event that did not require viral replication. In addition, we found
that granulocytes and inflammatory monocytes migrate from the
blood to the lungs of MHV-68-infected mice and express high
levels of surface TLR2, suggesting that these cells may contribute
to viral clearance and possibly play a relevant role as cytokine
producers via TLR2 activation. However, we cannot exclude that
resident cells of the respiratory tract and lungs expressing TLR2
also participate in the recognition of MHV-68. Our results also
suggest that TLR2 is not the sole MyD88-dependent receptor
implicated in the antiviral response against the virus since
MyD882/2 mice were highly susceptible to infection. While
TLR2 action appears to be central for efficient lung innate
immunity regulated in part by cytokine and more importantly by
type 1 IFN secretion, other MyD88-dependent mechanisms may
act in synergy with TLR2 for the regulation of protective
immunity against MHV-68. For example, other TLRs known to
signal via MyD88 such as TLR7, TLR8, and TLR9 have been
reported to play crucial roles in antiviral defense against other
herpesviruses ([9,14,28,29] and reviewed in [30]). The implication
of these receptors in the early lung innate immune response
against MHV-68 remains to be clarified.
Two different reports have investigated the implication of TLR
signaling during acute MHV-68 infection. Using in. infection with
a low dose of virus, Gargano et al. [15] observed that early viral
replication in the lungs is unaffected in MyD88-deficient mice
when compared to WT mice. Guggemoos et al. [14] investigated
the implication of TLR9 signaling in the control of MHV-68.
Using a high dose of virus, they observed that lung viral loads
were comparable in both WT as well as TLR92/2 mice
following in. infection. On the other hand, when MHV-68
infection was performed via the ip. route, spleen viral loads were
more elevated in TLR92/2 mice as compared to WT mice. Our
results suggest that TLR2 and downstream signaling pathways
dependent on MyD88 are important assets for early MHV-68
viral control in the lungs following in. infection with a high but
sublethal dose of virus. The discrepancies between these different
observations might be due to several factors including the dose of
virus inoculated, the infection route, as well as the innate
mechanism responsible for virus clearance in a particular organ.
While a low dose of virus during in. infection seems to be
managed in a MyD88-independent fashion, TLR2 and MyD88
are important for proinflammatory cytokine and type 1 IFN
secretion as well as for the control of pulmonary MHV-68 loads
following infection with a high dose of virus. The direct
implication of MyD88-dependent TLR2 signaling in MHV-68
control by lung epithelial cells, macrophages and by infiltrating
neutrophils and monocytes has yet to be investigated and should
clarify the role of this TLR pathway during acute MHV-68
infection. Guggemoos et al. observed that during ip. infection with
MHV-68, TLR9 seems to play a crucial role in spleens for an
Figure 5. Decreased type 1 IFN and enhanced MHV-68 loads in lungs of TLR2- and MyD88-deficient mice. (A and B) WT, TLR22/2 and
MyD882/2 mice (3 mice/group) were mock infected or infected in. with MHV-68 (10
5 PFU/mouse). Lung homogenates were prepared 24 hours post-
infection for IFN-a (A) and IFN-b (B) determination by ELISA. (C and D) WT, TLR22/2 and MyD882/2 mice (5 mice/group) were infected in. with
MHV-68 (10
5 PFU/mouse). Lung homogenates were prepared on days 3 and 5 post-infection for determination of viral load (C) and lung IL-6
concentration (D). Graphs are representative of three different experiments. Values significantly different (p,0.05) from WT mice are indicated (*).
doi:10.1371/journal.pone.0013742.g005
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observation may be explained by the differential TLR9 tissue
expression. In fact, this receptor is highly expressed in the spleen
while it is modestly expressed in lung tissue [31,32]. We observed
that TLR2 and MyD88-dependent signaling seems crucial for
lung defense during acute MHV-68 infection and for recognition
of MHV-68 particles in the lungs and spleen. These findings
highlight the importance of organ-specific innate responses
against MHV-68.
We have shown that MHV-68 stimulation leads to an
upregulation of TLR2 transcription in vivo. Since viral replication
is dispensable for such modulation, we can postulate that this event
is the consequence of a fast activation of the innate immune system
against acute MHV-68 infection. It is known that TLR2 can be
internalized to the Golgi apparatus following the binding to LTA
and it was also suggested that receptor internalization is required
for TLR2-dependent production of type 1 IFN [18,33]. Hypo-
thetically, this receptor trafficking event could be one of the
strategies used by the host for effective viral recognition and
increased antiviral response against MHV-68. In fact, assuming
that cells are able to increase detection of MHV-68 through
TLR2, this would imply a better response against MHV-68 and
therefore a reduction in viral burden. TLR2 upregulation is
naturally absent in TLR22/2 mice and might be reduced in
MyD882/2 mice, which could in part explain the reduction
observed in IL-6 and type 1 IFN secretion because of a lack of a
sufficient amount of functional TLR2 receptors. Therefore, the
increase in viral burden in the absence of MyD88 and TLR2
proteins could be a direct result of the lack of TLR2 upregulation
and associated cytokine secretion.
Type 1 IFNs are crucial toward the control MHV-68 during
acute infection [24]. A recent study by Barbalat et al. [18] showed
that TLR2 on inflammatory monocytes could recognize non-
nucleic acid components of viruses and induce production of type
1 IFN. Our results showing that TLR2 is both upregulated on the
surface of lung-migrating inflammatory monocytes and contrib-
utes to the production of type 1 IFN in MHV-68-infected mice are
consistent with this report. However, whether inflammatory
monocytes are actual type 1 IFN producers following their
migration to the lungs remains to be confirmed. Furthermore,
while IFN-a/b secretion was significantly inhibited in different
tissues of TLR22/2 and MyD882/2 mice, residual secretion
could still be detected indicating that alternative pathways,
independent of MyD88, may participate and/or compensate for
such secretion following MHV-68 stimulation. For example, other
pathways might include viral detection systems such as RIG-I-like
receptors (RLR), NOD-like receptors (NLRs) as well as TLR
signaling via the TRIF adaptor protein. These hypotheses are now
under investigation.
Together, the results presented in this study indicate that TLR2
is important for the activation of a rapid and efficient innate
response in the lungs following acute MHV-68 infection. Having
previously reported TLR2-dependent recognition of EBV by
human monocytes [13] and more recently, TLR9-mediated
recognition of this virus by human monocytes and plasmacytoid
dendritic cells [28], it will be important to investigate whether
Figure 6. Cytokine production in sera, lungs and spleens of mice upon MHV-68 treatment. WT, TLR22/2 and MyD882/2 mice were
injected iv. with mock control or UV-irradiated MHV-68 particles and sacrificed at 10 or 24 hours post-treatment. Concentration levels of IL-6 and IFN-
a were determined by ELISA in sera, lung and spleen homogenates after 24 hours. IFN-b levels were tested at 10 hours post-treatment. Data are
representative of two different experiments. Values significantly different (p,0.05) from WT mice are indicated by (*). N.D.: not detected.
doi:10.1371/journal.pone.0013742.g006
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humans.
Materials and Methods
Ethics Statement
All experimental protocols using mice were performed in
accordance with an internal review board-approved protocol at
CHUQ Research Center (Centre Hospitalier de l’Universite ´
Laval). This study was approved by the Comite ´ de protection des
animaux du CHUQ (approval #09-146-1).
Mice and MEFs culture
C57Bl/6 mice, 4–6 weeks old, were purchased from Charles
River (Quebec, Canada). TLR2- and MyD88-deficient mice were
kindly provided by Dr. Serge Rivest (CHUQ Research Center,
Universite ´ Laval, Quebec, Canada). TRIF-deficient mice were
kindly provided by Dr. T.-j. Lin (Dalhousie University, Halifax,
Canada). TLR2-LUC-AcGFP transgenic mice were generated in
the Transgenic and Knockout Facility of Research Centre of the
Centre Hospitalier de l’Universite ´ Laval, as previously reported
[34]. Murine embryonic fibroblasts (MEFs) were obtained
following overnight tryptic digestion (0.5% trypsin-EDTA solution
at 4uC) of 12 to 15-day-old embryos of C57Bl/6, TLR2-, MyD88-
and TRIF-deficient mice as detailed [35]. MEFs were cultured in
minimum essential medium (MEM) supplemented with 20% heat-
inactivated fetal bovine serum (FBS).
Viral preparation and titration
MHV-68 g2.4 strain, kindly provided by Dr. Bernadette Dutia
(University of Edinburgh, Edinburgh, UK), was amplified in baby-
hamster kidney (BHK-21) (ATCC, Manassas, VA, USA) cell line
as described previously [36]. Cells infected with purified virus were
cultured in MEM supplemented with 5% heat-inactivated FBS
until 90% of mortality was observed. Supernatant was then filtered
on 0.45 mm pore filter and viral particles were concentrated by
ultracentrifugation [37]. Uninfected-BHK-21 cells supernatant
was treated as above to produce mock control. Both viral
preparations and mock control were resuspended in MEM
medium for in vitro experiments or in saline solution (0.45% w/v
NaCl containing 0.25% w/v dextrose) for in vivo experiments. UV-
irradiated viral particles were obtained following incubation of
viral preparation under UV radiation (30 min, 265 nm) [38].
Viral load determination was performed by serial dilutions using a
standard plaque assay on Vero cell cultures as described [39].
Mice infection
Intranasal (in.) infections were performed with 25 ml of MHV-
68 preparation (10
5 viral particles) in saline solution. Intraperito-
neal (ip.) and intravenous (iv.) stimulations were performed using
100 ml of infectious particles (10
5 PFU) or UV-irradiated viral
preparation (10
5 or 10
7 viral particles). Inguinal and lumbar lymph
nodes of TLR2-LUC-AcGFP mice were isolated and resuspended
in TRIzol reagent (Invitrogen, Ontario, Canada) for DNA
isolation. At indicated time, sera were collected by cardiac
puncture and tested for IL-6 and IFN-a/b by ELISA. Lungs
and spleens were also harvested and triturated for cytokine
determination. Lung viral loads were determined by standard
plaque assay. For flow cytometry analysis, harvested lungs were
treated with collagenase to obtain single-cell suspension as
described [40].
Luciferase assay
Human embryonic kidney (HEK293) cell line (ATCC,
Manassas, VA, USA) was cultured in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% heat-inactivated FBS.
HEK293 (5610
4 cells/ml) were transiently co-transfected with
400 ng of either pDUO2-hMD2-CD14 (control human plasmid)
or pUNO-mTLR2-HA plasmids (Invivogen, San Diego, CA,
USA), using Escort transfection reagent (Sigma-Aldrich, Ontario,
Canada) along with 100 ng of NF-kB luciferase reporter plasmid.
Forty-eight hours following transfection, cells were stimulated for
6 hours with either mock, MHV-68 or the TLR2 ligand
Pam3CSK4 (1 mg/ml). Following stimulation, cells were lysed in
luciferase buffer (1% Triton, 10% glycerol, 20 mM Tris
phosphate, pH 7.8) and luciferase activity was measured by
luminometry. Relative light units (RLU) were normalized by
protein dosage using BCA protein assay kit (Pierce Biotechnology,
Rockford, IL, USA).
In vivo bioluminescence
Images of TLR2-LUC-AcGFP transgenic mice were obtained
using IVIS Imaging System (Xenogen, Alameda, CA, USA) fifteen
to twenty-five minutes following ip. injection of D-Luciferin
(150 mg/kg) (Gold Biotechnology, St. Louis, MO, USA) dissolved
in saline solution. Mice were anesthetised under 2% isoflurane in
100% oxygen at a flow rate of 2 L/min and placed in a heated,
light-tight imaging chamber. Images were collected using a high
sensitivity CCD camera with wavelengths ranging from 300–
600 nm for an exposure time of one minute. Bioluminescence was
normalized and displayed in physical units of surface radiance
(photons/s
21/cm
22/steradian
21) using Living Image 2.5 software
(Xenogen) which expresses light intensity as a color gradient (from
violet to red). Bioluminescence was considered significant when
light emission was greater than mock-injected control.
DNA extraction and PCR analyses
Total DNA was extracted from lymph nodes of mock- and
MHV-68-infected mice using TRIzol reagent following the
manufacturer’s instructions (Invitrogen, Ontario, Canada) and
amplified by qPCR using SYBR Green supermix (Invitrogen,
Ontario, Canada). qPCR was performed using MHV-68 gB 20-
mers (forward: 59-ggcccaaattcaatttgcct-39 and reverse 59-ccctgga-
caactcctcaagc-39) starting by 2 min at 50uC then 10 min at 95uC,
followed by 40 cycles of denaturation at 95uC for 15 sec, 58uC for
1 min and followed by a temperature gradient from 60 to 99uC for
20 sec. Analysis was performed using RG-3000 from Corbett
Research and Rotor Gene 6 software (Montreal Biotech Inc.,
Quebec, Canada).
Cytokine quantification
MEFs (5610
4 cells/ml) were stimulated with lipopolysaccharide
(LPS, 1 or 5 mg/ml), Pam3CSK4 (Pam, 1 mg/ml), LTA (10 mg/
mL) or with either infectious or UV-irradiated MHV-68 particles
or transfected with poly(I:C) (5 mg/mL) using Lipofectamine
reagent (Invitrogen, Ontario, Canada) for the indicated periods
of time and cell-free supernatants were harvested for IL-6
(eBiosciences, San Diego, CA, USA), IFN-a and IFN-b (PBL
Biomedical Laboratories, Piscataway, NJ, USA) quantification by
ELISA. Sera from uninfected and infected mice as well as organ
homogenate supernatants were tested for IL-6, IFN-a and IFN-b
by ELISA.
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Single-cell suspensions obtained from collagenase-treated lungs
of mock- and MHV-68-infected mice were first stained with
allophycocyanin-conjugated-anti-CD115 (eBioscience, San Diego,
CA, USA), Pacific Blue-conjugated-anti-Ly6-G/Ly6-C(GR-1)
(BioLegend, San Diego, CA, USA), followed by labelling with
anti-mTLR2 monoclonal antibody (Invivogen, San Diego, CA,
USA) and fluorescein-conjugated-anti-mouse antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) to
determine expression levels of TLR2 on different cell populations.
Flow cytometry analyses were performed using BD LSR II (BD
Biosciences, Ontario, Canada) on 10,000 cells per sample.
Statistical Analyses
Data were analyzed by one-tailed analysis of variance
(ANOVA) followed by Newman-Keuls post-hoc test using
PRISM5 software. Differences were considered significant at
p,0.05.
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